Swiss drug developer Windward Bio files for US IPO
Windward Bio filed for a US initial public offering on Friday, becoming the latest drug developer seeking to capitalize on renewed investor interest in biotech listings.
Windward Bio filed for a US initial public offering on Friday, becoming the latest drug developer seeking to capitalize on renewed investor interest in biotech listings.